PMLiVE9d
PMLiVE’s T40 – results announced!
The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...
PMLiVE7d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...
PMLiVE7d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...
PMLiVE7d
Eli Lilly and insitro collaborate to advance new treatments for metabolic diseases
Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic ...
PMLiVE12d
AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn
AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...
PMLiVE17d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
PMLiVE16d
Results from Global Pharmaceutical Customer Experience survey
Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...
PMLiVE15d
Chiesi Group invests €400m to establish biotech centre of excellence in Italy
Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...
PMLiVE9d
GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...
PMLiVE15d
Top-10 ways for Pharma to leverage AI according to…AI
Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to only a few ...
PMLiVE17d
Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis
Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in moderate-to-severe scalp psoriasis. Data from the ongoing ...
PMLiVE11d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and Astellas’ Xtandi (enzalutamide) in patients with metastatic castration-sensitive ...